Stephanie Mastrorocco

• Successfully launched Xtandi in non-metastatic castration sensitive prostate cancer with biochemical recurrence at high risk for metastasis, metastatic castration sensitive prostate cancer, and castration resistant prostate cancer to academic/community oncologists and urologists.
• Achieved National Sales Summit Club Award. Top 5% in the Nation the first year Xtandi was approved by the FDA in 2012
• Achieved National Sales Alpine Award. Top 15% in the Nation- 2015
• Achieved National Sales Peak Performer Award. Top 10% in the Nation- 2022
• Expanded Xtandi sales and market share growth in five advanced prostate cancer indications. (2012, 2014, 2017, 2019, 2023)
• Appointed Xtandi Certified Field Trainer. Responsible for training new hires in home-office training classes and field base training. (2018-2020)
• Awarded the Astellas National Apogee Award for cross-functional business unit collaboration.
• Fostered relationships and provided value added services to the largest LUGPA (Integrated Medical Professionals- Solaris Health) account in the country. (2016)
• Supported Health Systems initiatives as a Region Reimbursement point through training workshops to target managed care step edits.
• Assisted LUGPA (Integrated Medical Professionals- Solaris Health) account as they built their in-office dispensing pharmacy, provided resources to meet account needs across divisional offices.
• Developed and executed business plans with oncology/urology accounts.
• Cultivated and managed relationships with Key Opinion Leaders, C-Suite members, reimbursement patient liaisons, researchers, and community partners.
• Collaborated with GU Oncology Nurse Navigators within academic/ community cancer centers
• Supported patient initiatives, disease state education and branded market programs.
• Led and facilitated Intensify Oncology workshops to inspire, educate and share best practices to oncology team members to drive performance.

· Successfully launched Tarceva in NSCLC, changing the paradigm in lung cancer treatment.

· Exceeded Tarceva goal attainments 2006- 107.96 %; 2007- 102.2%; 2009- 104.97%; 2011- 110.24%; 2012- 110%

· Expanded Tarceva market share growth and sales in three product indications. (Front Line NSCLC EFGR mutation indication, NSCLC Maintenance indication, Pancreatic Cancer indication)

· Selected to be on the Selling Model Task Force Committee- 2011

· Worked with specialty pharmacies to increase utilization of Tarceva.

· Nominated to be on the Tarceva Product Team and collaborated with the marketing department on branded and unbranded educational resources- 2008

* Responsible for the launch and promotion of the first-in-class antiemetic, Emend in April 2003.

* Provided education to increase awareness of the prevalence of chemotherapy-induced nausea and vomiting.

* Presidents Club Award Winner; Ranked #2 in the Nation- 2004

* Achieved 177.9% to plan for Emend sales; Ranked #1 in the Nation- 2004

* Received sales award for achieving the sixth highest market share change in the nation- April thru December 2003.

* Achieved 217% to plan for Emend sales in the first month of product launch- April 2003.

* Promoted to Senior Oncology Specialty Representative- October 2003

* Gained formulary status in multiple hospital institutions in territory assignment.

* Implemented official group practice antiemetic protocols for Emend with key oncology offices.

* Worked National (ASCO) and local conferences.

* Responsible for the promotion of Biaxin, Prevacid, Omnicef, and Hytrin to primary care and specialty physicians including pulmonologists, otolaryngologists, allergists, infectious disease, and gastroenterologist.

* Appointed Regional Field Trainer; Responsible for the training and development of new and existing sales representatives; Demonstrated effective sales presentations, territory and resource management.

* Achieved highest Prevacid market share and market share growth in the district from 1999-2001.

Maintained Prevacid market share above national and regional averages from 1999-2001.

* Maintained Biaxin market share above regional and district average; Achieved achievement awards in 1998.